Therapeutic drug monitoring of mycophenolates in kidney transplantation: Report of The Transplantation Society consensus meeting

Transplantation Reviews

Volumn 25, Issue 2, 2011, Pages 58-64

  Le Meur, Yannick ^a   Borrows, Richard ^b   Pescovitz, Mark D ^c   Budde, Klemens ^d   Grinyo, Josep ^e   Bloom, Roy ^f   Gaston, Robert ^g   Walker, Rowan G ^h   Kuypers, Dirk ⁱ   van Gelder, Teun ^j   Kiberd, Bryce ^k  

^a SERVICE DE RHUMATOLOGIE   (France)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h ROYAL MELBOURNE HOSPITAL   (Australia)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k DALHOUSIE UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTON PUMP INHIBITOR; RAPAMYCIN; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ALLOGRAFT; ANEMIA; AREA UNDER THE CURVE; CONCENTRATION RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; HISTOPATHOLOGY; HUMAN; HYPOALBUMINEMIA; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LEUKOPENIA; LOW DRUG DOSE; POLYOMA VIREMIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VIREMIA; VIRUS INFECTION;

EID: 79953718025     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2011.01.002     Document Type: Review

References (48)

1. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009, 9(Suppl 3):S1-S155. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group.
2. Knight S.R., Morris P.J. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation 2008, 85:1675-1685.
3. Flechner S.M., Feng J., Mastroianni B., et al. The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression. Transplantation 2005, 79:926-934.
4. van Gelder T., Le Meur Y., Shaw L.M., et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006, 28:145-154.
5. Kiberd B.A., Lawen J., Fraser A.D., Keough-Ryan T., Belitsky P. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant 2004, 4:1079-1083.
6. Borrows R., Chusney G., Loucaidou M., et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. Am J Transplant 2006, 6:121-128.
7. Gaston R.S., Kaplan B., Shah T., et al. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant 2009, 9:1607-1619. Epub 2009 May 20.
8. Hale M.D., Nicholls A.J., Bullingham R.E., et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998, 64:672-683.
9. van Gelder T., Hilbrands L.B., Vanrenterghem Y., et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999, 68:261-266.
10. Le Meur Y., Büchler M., Thierry A., et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007, 7:2496-2503. Epub 2007 Oct 1.
11. van Gelder T., Silva H.T., de Fijter J.W., et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008, 86:1043-1051.
12. Knoll G.A., MacDonald I., Khan A., Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003, 14:2381-2386.
13. Pelletier R.P., Akin B., Henry M.L., et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003, 17:200-205.
14. Opelz G., Döhler B. Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation 2008, 86:371-376.
15. Hazzan M., Buob D., Labalette M., et al. Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial. Transplantation 2006, 82:657-662.
16. De Fijter J.W., Mourer J.S., den Hartigh J., Mallat M.J., Berger S.P. Concentration-controlled systemic exposure provides improved safety after CNI or MMF withdrawal. Am J Transplant 2007, 7(Suppl 2):208-209.
17. Le Meur Y., Touchard G., Glowacki F., et al. Optimisation of mycophenolic acid (MPA) exposure for early steroid withdrawal in kidney graft recipients: the OPERA trial. Am J Transplant 2009, 9:341.
18. de Winter B.C., van Gelder T., Mathot R.A., et al. Limited sampling strategies drawn within 3 hours postdose poorly predict mycophenolic acid area-under-the-curve after enteric-coated mycophenolate sodium. Ther Drug Monit 2009, 31:585-591.
19. Sommerer C., Müller-Krebs S., Schaier M., et al. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. Br J Clin Pharmacol 2010, 69:346-357.
20. Budde K., Glander P., Diekmann F., et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 2004, 5:333-345.
21. Gourishankar S., Houde I., Keown P.A., et al. The CLEAR study: a 5-day, loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. Clin J Am Soc Nephrol 2010, 5:1282-1289. Epub 2010 May 24.
22. Mourad M., Malaise J., Chaib Eddour D., et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 2001, 47:88-94.
23. Kuypers D.R., de Jonge H., Naesens M., et al. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther 2008, 30:673-683.
24. Glander P., Sommerer C., Arns W., et al. Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients. Clin J Am Soc Nephrol 2010, 5:503-511. Epub 2010 Feb 11.
25. Davies N.M., Grinyó J., Heading R., Maes B., Meier-Kriesche H.U., Oellerich M. Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. Nephrol Dial Transplant 2007, 22:2440-2448. Epub 2007 Jun 8.
26. Heller T., van Gelder T., Budde K., et al. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. Am J Transplant 2007, 7:1822-1831. Epub 2007 May 26.
27. van Hest R.M., van Gelder T., Bouw R., et al. Time-dependent clearance of mycophenolic acid in renal transplant recipients. Br J Clin Pharmacol 2007, 63:741-752. Epub 2007 Jan 3.
28. Shaw L.M., Korecka M., Venkataramanan R., Goldberg L., Bloom R., Brayman K.L. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003, 3:534-542.
29. Pescovitz M.D., Guasch A., Gaston R., et al. Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am J Transplant 2003, 3:1581-1586. Erratum in: Am J Transplant. 2004 Nov;4:1928.
30. van Hest R.M., Mathot R.A., Pescovitz M.D., Gordon R., Mamelok R.D., van Gelder T. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006, 17:871-880. Epub 2006 Feb 1.
31. van Schaik R.H., van Agteren M., de Fijter J.W., et al. UGT1A9-275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther 2009, 86:319-327. Epub 2009 Jun 3.
32. Büchler M., Lebranchu Y., Bénéton M., et al. Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment. Clin Pharmacol Ther 2005, 78:34-42.
33. Grinyó J.M., Ekberg H., Mamelok R.D., et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Nephrol Dial Transplant 2009, 24:2269-2276. Epub 2009 Apr 8.
34. Cattaneo D., Perico N., Gaspari F., Gotti E., Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002, 62:1060-1067.
35. Miura M., Satoh S., Inoue K., et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther Drug Monit 2008, 30:46-51.
36. Kofler S., Shvets N., Bigdeli A.K., et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. Am J Transplant 2009, 9:1650-1656. Epub 2009 Jun 10.
37. Rupprecht K., Schmidt C., Raspé A., et al. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. J Clin Pharmacol 2009, 49:1196-1201.
38. Budde K., Bauer S., Hambach P., et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant 2007, 7:888-898. Erratum in: Am J Transplant. 2007 Aug;7(8):2057.
39. Budde K., Tedesco-Silva H., Pestana J.M., et al. Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: implications for therapeutic drug monitoring. Ther Drug Monit 2007, 29:381-384.
40. Shaw L.M., Holt D.W., Oellerich M., Meiser B., van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001, 23:305-315.
41. van Gelder T., Tedesco Silva H., de Fijter J.W., et al. Renal transplant patients at high risk of acute rejection benefit from adequate exposure to mycophenolic acid. Transplantation 2010, 89:595-599.
42. Ekberg H., Grinyó J., Nashan B., et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007, 7:560-570. Epub 2007 Jan 22.
43. Kuypers D.R., Ekberg H., Grinyó J., et al. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients. Clin Pharmacokinet 2009, 48:329-341.
44. Le Meur Y., Kamar N., Rondeau E., et al. MPA exposure in patients with early steroid withdrawal: comparison between two MMF based immunosuppressive regimens, concentration-controlled versus fixed dose. Am J Transplant 2009, 9:508.
45. Gourishankar S., Houde I., Keown P.A., et al. The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. Clin J Am Soc Nephrol 2010, 5:1282-1289. Epub 2010 May 24.
46. Pescovitz M.D., Conti D., Dunn J., et al. Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. Clin Transplant 2000, 14:179-188.
47. Glander P., Sommerer C., Arns W., et al. Dose proportionality of mycophenolic acid is limited by renal function early after renal transplantation. Am J Transplant 2010, 4:323.
48. Rousseau A., Laroche M.L., Venisse N., et al. Cost-effectiveness analysis of individualized mycophenolate mofetil dosing in kidney transplant patients in the APOMYGRE trial. Transplantation 2010, 89:1255-1262.